Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhalation pharmaceutical composition containing budesonide and terbutaline

A technology for inhaling drugs and terbutaline, which can be used in drug combinations, medical preparations containing active ingredients, drug delivery, etc. Asthma latency, good effect

Inactive Publication Date: 2013-06-19
TIANJIN JINYAO GRP
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The literature also pointed out that the ideal ICS should be a perfect combination of effectiveness and safety. Although ICS has made great progress in the safety of treatment compared with systemic hormones, it still cannot meet the needs of clinical treatment.
Long-term use of high-dose ICS will still cause adverse reactions such as adrenal cortex suppression, and the so-called safe dose of ICS (sub-large dose) alone cannot effectively control most moderate-to-severe asthma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalation pharmaceutical composition containing budesonide and terbutaline
  • Inhalation pharmaceutical composition containing budesonide and terbutaline
  • Inhalation pharmaceutical composition containing budesonide and terbutaline

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-1

[0041] Example 1-1 (100:250)

[0042] Budesonide 50 mg, dissolved in ethanol, filtered, and the filtrate was spray-dried to make the average particle size reach 5.3 μm (95% particle size range is 4.1-8.0 μm)

[0043] Terbutaline sulfate 250mg was dissolved in ethanol, after filtration, the filtrate was spray-dried to make the average particle size reach 5.6 μm (95% particle size range was 4.5-8.0 μm),

[0044] Budesonide superfine powder 50mg, fully mixed with terbutaline sulfate micropowder.

[0045] 20 g of anhydrous lactose was micronized by a flow energy mill to an average particle size of 35 μm, and the mixture of budesonide micropowder, budesonide ultrafine powder and terbutaline sulfate micropowder was added respectively, after mixing, passed through a 200-mesh sieve for 3 times and mixed Divide evenly into No. 3 capsules. Each capsule contains 100 μg of budesonide and 250 μg of terbutaline sulfate.

[0046] The process conditions are as follows: inlet temperature is...

Embodiment 1-2

[0048] According to the formulation and process of Example 1-1, the carrier was changed to octaacetate-D-cellobiose ester with an average particle size of 45 μm. Prepare powder spray.

Embodiment 1-3

[0050] According to the formula and process of Example 1-1, budesonide was changed to micropowder obtained by spray drying. Prepare powder spray.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides an inhalation pharmaceutical composition containing budesonide and terbutaline, comprising terbutaline as an active ingredient or one or more pharmaceutically acceptable salts or esters thereof thereof and budesonide, and one or more pharmaceutical excipients being suitable for inhalation.

Description

technical field [0001] The invention relates to a pharmaceutical composition, which is an inhalation pharmaceutical composition containing corticosteroids and NOS inhibitors. Background technique [0002] Glucocorticoids have anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive effects, and are widely used in the treatment of allergic and autoimmune inflammatory diseases. Such as connective tissue disease, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, acute leukemia, etc. It is also used for some serious infections, poisoning, and malignant lymphoma. treat. [0003] Asthma is a chronic airway inflammation characterized by reversible airway obstruction and increased airway responsiveness. Airway obstruction is caused by two factors: increased secretions caused by bronchial mucosal inflammation, mucosal edema, and smooth muscle spasm stimulated by inflammation; while asthma Inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/137A61K9/18A61K9/12A61P11/06
Inventor 李静
Owner TIANJIN JINYAO GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com